IHI - iShares US Medical Devices ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
223.89
+3.50 (+1.59%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close220.39
Open221.83
Bid0.00 x 1200
Ask0.00 x 900
Day's Range221.72 - 223.89
52 Week Range178.75 - 228.90
Volume188,867
Avg. Volume223,098
Net Assets2.78B
NAV223.78
PE Ratio (TTM)N/A
Yield0.25%
YTD Return12.02%
Beta (3Y Monthly)1.08
Expense Ratio (net)0.43%
Inception Date2006-05-01
Trade prices are not sourced from all markets
  • Analysts Are Optimistic ahead of Boston Scientific’s Q4 Results
    Market Realist16 days ago

    Analysts Are Optimistic ahead of Boston Scientific’s Q4 Results

    Analysts Are Optimistic ahead of Boston Scientific's Q4 ResultsAnalysts’ recommendations and target priceBoston Scientific (BSX) is scheduled to post its fourth-quarter and 2018 earnings results on February 6, 2019. In this article, we’ll

  • ETF Trends24 days ago

    Healthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak Outlook

    Healthcare ETFs weakened Wednesday after Abbot Laboratories (ABT) slipped on a revenue miss and revealed an uninspiring forecast for the first quarter of the new year. The Health Care Select Sector SPDR ETF (XLV) fell 0.3% on Wednesday while the S&P 500 was 0.1% lower. Abbot Laboratories' quarterly revenue fell short of expectations due to lower sales of generic drugs in the emerging markets, Reuters reports.

  • Top Performing Health Care ETFs of 2018
    Investopedialast month

    Top Performing Health Care ETFs of 2018

    The health care sector spent much of 2018 as the strongest performer across the market. For investors looking to take part in the health care sector, one of the easiest and most popular options is an exchange-traded fund (ETF). Given the popularity of the health care sector ETF space and the relative success of this corner of the financial world, there were several health care ETFs which were among the top performing ETFs overall for 2018.

  • What’s Driving TransEnterix Stock on January 8?
    Market Realistlast month

    What’s Driving TransEnterix Stock on January 8?

    On January 8, TransEnterix (TRXC) rose 11.15% compared to its previous closing price and reached $2.99 in its pre-market trading session. On January 7, TransEnterix issued a press release announcing its preliminary operational and financial performance for the fourth quarter and fiscal 2018. Based on the closing price on January 7, TransEnterix reported returns of 9.80% in the last week, -13.50% in the last month, and -53.70% in the last quarter.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zackslast month

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • 10 Top-Ranked ETFs That Crushed the Market in 2018
    Zackslast month

    10 Top-Ranked ETFs That Crushed the Market in 2018

    While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.

  • These 3 Top Sector Plays Are Still Trouncing The Stock Market
    Investor's Business Daily2 months ago

    These 3 Top Sector Plays Are Still Trouncing The Stock Market

    What market sell-off? These three sector ETFs wrapped up 2018 with double-digit gains even though Wall Street stumbled in October and fell hard.

  • 4 Sector ETFs Surviving the Market Rout in 2018
    Zacks2 months ago

    4 Sector ETFs Surviving the Market Rout in 2018

    While most of the sectors are in red this year, a few ETFs are easily surviving the market rout.

  • A Look at the Christmas Tree of Top-Ranked ETFs
    Zacks2 months ago

    A Look at the Christmas Tree of Top-Ranked ETFs

    We have built a tree with the top-ranked ETFs that have the potential to outperform in 2019.

  • 3 Best ETF Ideas For Investors Include Dividend, China FANG Plays
    Investor's Business Daily2 months ago

    3 Best ETF Ideas For Investors Include Dividend, China FANG Plays

    Beaumont Capital Management aims to make investors comfortable by helping capture upside gains and protect against steep potential losses.

  • A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
    Market Realist2 months ago

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.

  • How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
    Market Realist2 months ago

    How Does Medtronic’s Restorative Therapies & Diabetes Group Look?

    Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty, and Pain therapies. Medtronic’s Restorative Therapies Group generated revenues of $2.0 billion in the second quarter of fiscal 2019 compared to $1.9 billion in the second quarter of fiscal 2018, reflecting ~7% YoY growth.

  • Top Sector ETFs of 2018
    Zacks2 months ago

    Top Sector ETFs of 2018

    These sector ETFs exceled in 2018 despite a few severe broader market crashes.

  • ETF Trends3 months ago

    ETFs to Help Investors Pick and Choose Their Market Exposures

    Markets have often rallied in the months after midterm elections (see chart below), but we are focused on what the new government makeup could mean for these sectors," Christopher Dhanraj, Director and Head of iShares Investment Strategy, said in a research note. Specifically, Dhanraj highlighted three U.S. segments to closely watch ahead. Something like the iShares U.S. Aerospace & Defense ETF (ITA) can be a pure play for those seeking exposure to the defense sector.

  • Wall Street Analysts Are Mostly Positive on Abiomed
    Market Realist3 months ago

    Wall Street Analysts Are Mostly Positive on Abiomed

    On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23. Abiomed stock rose from $187.41 at the close of market on December 29, 2017, to $311.15 at the close of market on November 26, 2018, reflecting a ~66% year-to-date rise.

  • Why Analysts Are Mostly Positive on Boston Scientific Stock
    Market Realist3 months ago

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.

  • Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
    Market Realist3 months ago

    Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date

    Intuitive Surgical’s (ISRG) stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018, reflecting a ~34% year-to-date rise.

  • Inside General Electric’s Healthcare Business Unit Spin-Off Plan
    Market Realist3 months ago

    Inside General Electric’s Healthcare Business Unit Spin-Off Plan

    As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.

  • ETF Trends3 months ago

    Leveraged Healthcare ETF Gains On Midterm Election Results

    Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...

  • ETF Trends3 months ago

    Healthcare ETFs in Focus Ahead of Election Day

    Count the iShares US Medical Devices ETF (NYSEArca: IHI) and the iShares US Healthcare ETF (NYSEArca: IYH) among the healthcare exchange traded funds that could be affected by the results of the upcoming ...

  • Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
    Market Realist4 months ago

    Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

    Thermo Fisher Scientific (TMO) reported its third quarter of 2018 results today, October 24. It surpassed Wall Street analysts’ estimates for both EPS and revenue. Its non-GAAP EPS was $2.62, and its revenues were $5.92 billion. That compares to analysts’ EPS estimate of $2.55 on revenues of $5.7 billion.

  • Thermo Fisher’s Third-Quarter Revenue Estimates
    Market Realist4 months ago

    Thermo Fisher’s Third-Quarter Revenue Estimates

    As we discussed in the previous part, Wall Street analysts expect Thermo Fisher Scientific (TMO) to report 11.5% revenue growth to $5.70 billion during the third quarter. Thermo Fisher provides products and services through its brands including Thermo Scientific, Fisher Scientific, Invitrogen, Unity Lab Services, and Applied Biosystems.

  • Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings
    Market Realist4 months ago

    Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings

    Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.

  • What to Expect from Medtronic’s Diabetes Segment
    Market Realist4 months ago

    What to Expect from Medtronic’s Diabetes Segment

    In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depositary share (or $29.25 per ordinary share), which amounts to a total of $1.64 billion (or $1.34 billion). Both companies’ boards of directors unanimously approved the transaction.

  • ETF Trends4 months ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.